無細胞療法市場：骨格、用途別-2025～2030年の世界予測

無細胞療法市場は2023年に110億7,000万米ドルと評価され、2024年には124億9,000万米ドルに達すると予測され、CAGR 13.37％で成長し、2030年には266億5,000万米ドルに達すると予測されています。

再生医療の最先端セグメントである無細胞療法は、細胞外マトリックス、成長因子、サイトカインなどの無細胞成分を用いて組織の修復と再生を促進します。無細胞療法の必要性は、従来の細胞療法では免疫学的リスクが生じたり、実用的でないような病態に対処できる可能性があることから生じています。創傷治癒や整形外科的修復から心臓血管や神経治療まで、その応用範囲は広いです。主要最終用途セグメントには、病院、研究機関、外来手術センターなどがあります。市場成長の主要原動力は、技術の進歩、認知度の向上、慢性疾患の増加です。個別化医療のアプローチや、送達と効能を強化するためのナノ技術による細胞成分の統合に機会が溢れています。企業は、特定の病状に合わせたソリューションの開発を目的とした研究開発提携や共同研究に投資することで、こうした動向を活用することができます。

しかし、いくつかの課題が市場の成長に影響を与えています。細胞培養療法は、場合によってはより広範な検証や標準化プロセスを必要とするため、規制上のハードルは依然として大きな懸念事項となっています。長期的な有効性については懐疑的な見方もあり、関係者の信頼を得るためには包括的な臨床検査とデータが必要です。さらに、R&Dに関連する高コストは、製造の複雑さとともに新規参入の妨げとなり、市場競争全体に影響を及ぼす可能性があります。

イノベーションは、自然の組織環境を模倣し、ヒトの生理機能とのより良い統合を達成できる新規生体材料の開発において追求するのが最善です。細胞成分の保存と輸送中の安定性と生物活性の改善に焦点を当てた調査セグメントは、普及のために不可欠です。市場力学を理解すると、北米と欧州は医療インフラが発達しているため成長軌道が支配的である一方、アジア太平洋は医療投資の増加により大きな可能性を秘めていることがわかる。企業は、パートナーシップを活用した適応戦略の構築と未開拓の地域市場の開拓に注力し、この進化する情勢下で競合を維持すべきです。

市場力学：急速に進化する無細胞療法市場の主要市場洞察を公開

無細胞療法市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患と加齢に関連した疾患の有病率の増加
  • 再生医療と幹細胞研究を推進する政府の取り組み
  • 無細胞生体材料とスマート生体材料の利用可能性の増加
• 市場抑制要因
  • 熟練研究者の不足と限られた償還オプション
• 市場機会
  • 世界の無細胞療法の進歩と研究開発
  • 病院や医療機関による無細胞療法プロジェクトの増加
• 市場課題
  • 再生医療と細胞治療に関する複雑な規制

ポーターのファイブフォース：無細胞療法市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：無細胞療法市場における外部からの影響の把握

外部マクロ環境要因は、無細胞療法市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：無細胞療法市場における競合情勢の把握

無細胞療法市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：無細胞療法市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、無細胞療法市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：無細胞療法市場における成功への道筋を描く

無細胞療法市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患や加齢に伴う疾患の増加
    • 再生医療と幹細胞調査を推進する政府の取り組み
    • 無細胞とスマート生体材料の利用可能性の向上
  • 抑制要因
    • 熟練した調査人材の不足と限られた償還オプション
  • 機会
    • 世界中の無細胞療法の進歩と研究開発
    • 病院や医療機関が実施する無細胞療法プロジェクトの増加
  • 課題
    • 再生医療と無細胞療法に関する複雑な規制
• 市場セグメンテーション分析
  • 骨格：細胞外マトリックスのサポートの優先的な無細胞療法
  • 用途：腫瘍学の腫瘍部位を標的とした無細胞療法の開発
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 無細胞療法市場：骨格別

• イントロダクション
• 細胞含有ハイドロゲル
• 細胞外マトリックス（ECM）
• 熱溶解積層法（FDM）

第7章 無細胞療法市場：用途別

• イントロダクション
• 心臓病学
• 消化器内科
• 肝臓病学
• 神経学
• 腫瘍学

第8章 南北アメリカの無細胞療法市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋の無細胞療法市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの無細胞療法市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • Humacyte、血管外傷患者の治療におけるヒト無細胞血管（HAV）の第2/3相検査で良好なトップライン結果を発表
  • FDA、1型糖尿病の細胞療法「ランティドラ」を承認
  • Humacyte、ウクライナの最前線病院に血管外傷の治療用にヒト無細胞血管（HAV）を提供
• 戦略分析と提言

企業一覧

• Allergan Inc. by Abbvie Inc.
• AlloSource
• Aziyo Biologics
• Baxter International
• Becton, Dickinson and Company
• BioHorizons, Inc.
• EnColl Corporation
• Engitix Ltd
• Fidia Farmaceutici S.p.A
• GSK PLC
• Humacyte, Inc.
• In2Bones Global by CONMED Corporation
• Integra LifeSciences Corporation
• LifeNet Health
• MiMedx Group
• Organicell Regenerative Medicine, Inc.
• Organogenesis Holdings Inc.
• Reprise Biomedical, Inc.
• Sanofi S.A.
• Smith & Nephew PLC
• Stryker Corporation
• Tissue Regenix
• Vascudyne, Inc.
• Zimmer Biomet

LIST OF FIGURES

• FIGURE 1. ACELLULAR THERAPY MARKET RESEARCH PROCESS
• FIGURE 2. ACELLULAR THERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ACELLULAR THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ACELLULAR THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. ACELLULAR THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ACELLULAR THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ACELLULAR THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ACELLULAR THERAPY MARKET DYNAMICS
• TABLE 7. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY CELL LADEN HYDROGEL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY EXTRACELLULAR MATRIX (ECM), BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY FUSED DEPOSITION MODELING (FDM), BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY HEPATOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 20. ARGENTINA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 22. BRAZIL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 23. BRAZIL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 24. CANADA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 25. CANADA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 26. MEXICO ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 27. MEXICO ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 29. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 32. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 33. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 34. AUSTRALIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 35. AUSTRALIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 36. CHINA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 37. CHINA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. INDIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 39. INDIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. INDONESIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 41. INDONESIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. JAPAN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 43. JAPAN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 44. MALAYSIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 45. MALAYSIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. PHILIPPINES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 47. PHILIPPINES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. SINGAPORE ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 49. SINGAPORE ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. SOUTH KOREA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 51. SOUTH KOREA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. TAIWAN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 53. TAIWAN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. THAILAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 55. THAILAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. VIETNAM ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 57. VIETNAM ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 59. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 61. DENMARK ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 62. DENMARK ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. EGYPT ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 64. EGYPT ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. FINLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 66. FINLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. FRANCE ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 68. FRANCE ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. GERMANY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 70. GERMANY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 71. ISRAEL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 72. ISRAEL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. ITALY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 74. ITALY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. NETHERLANDS ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 76. NETHERLANDS ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. NIGERIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 78. NIGERIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. NORWAY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 80. NORWAY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. POLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 82. POLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. QATAR ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 84. QATAR ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. RUSSIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 86. RUSSIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. SAUDI ARABIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 88. SAUDI ARABIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH AFRICA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH AFRICA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. SPAIN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 92. SPAIN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. SWEDEN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 94. SWEDEN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 95. SWITZERLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 96. SWITZERLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. TURKEY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 98. TURKEY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. UNITED ARAB EMIRATES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 100. UNITED ARAB EMIRATES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. UNITED KINGDOM ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
• TABLE 102. UNITED KINGDOM ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. ACELLULAR THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 104. ACELLULAR THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

The Acellular Therapy Market was valued at USD 11.07 billion in 2023, expected to reach USD 12.49 billion in 2024, and is projected to grow at a CAGR of 13.37%, to USD 26.65 billion by 2030.

Acellular therapy, a cutting-edge segment within regenerative medicine, involves using cell-free components such as extracellular matrix, growth factors, and cytokines to promote tissue repair and regeneration. The necessity for acellular therapy arises from its potential to address conditions where traditional cellular therapies may introduce immunological risks or be impractical. Applications are vast, ranging from wound healing and orthopedic repairs to cardiovascular and neurological therapy. Key end-use segments include hospitals, research institutes, and ambulatory surgical centers. Market growth is largely driven by technological advancements, increasing awareness, and a rise in chronic disease prevalence. Opportunities abound in personalized medicine approaches and integrating acellular components with nanotechnology for enhanced delivery and efficacy. Companies can capitalize on these trends by investing in R&D partnerships and collaborations aimed at developing tailored solutions for specific medical conditions.

However, several challenges affect market progression. Regulatory hurdles remain a significant concern as acellular therapies, in some cases, need more extensive validation and standardization processes. Skepticism exists around long-term efficacy, pushing the need for comprehensive clinical trials and data to gain stakeholder confidence. Additionally, high costs associated with R&D, alongside manufacturing complexities, can hinder entry for new players, affecting overall market competition.

Innovations are best pursued in the development of novel biomaterials that can mimic natural tissue environments and achieve better integration with human physiology. Research areas focusing on improving the stability and bioactivity of acellular components during storage and transport will be critical for widespread implementation. Understanding market dynamics reveals a growth trajectory dominated by North America and Europe due to their developed healthcare infrastructure, while Asia-Pacific shows immense potential due to increasing healthcare investments. Businesses should focus on building adaptive strategies leveraging partnerships and exploring untapped regional markets to maintain a competitive edge in this evolving landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acellular Therapy Market

The Acellular Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing prevalence of chronic diseases and age-related conditions
  • Government initiatives to propel regenerative medicine and stem cell research
  • Increased availability of acellular and smart biomaterials
• Market Restraints
  • Lack of skilled research personnel and limited reimbursement options
• Market Opportunities
  • Advancements and R&D in acellular therapy worldwide
  • Rising number of acellular therapy projects undertaken by hospitals and medical entities
• Market Challenges
  • Complex regulations pertaining to regenerative medicine and acellular therapies

Porter's Five Forces: A Strategic Tool for Navigating the Acellular Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acellular Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acellular Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acellular Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acellular Therapy Market

A detailed market share analysis in the Acellular Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acellular Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acellular Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acellular Therapy Market

A strategic analysis of the Acellular Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acellular Therapy Market, highlighting leading vendors and their innovative profiles. These include Allergan Inc. by Abbvie Inc., AlloSource, Aziyo Biologics, Baxter International, Becton, Dickinson and Company, BioHorizons, Inc., EnColl Corporation, Engitix Ltd, Fidia Farmaceutici S.p.A, GSK PLC, Humacyte, Inc., In2Bones Global by CONMED Corporation, Integra LifeSciences Corporation, LifeNet Health, MiMedx Group, Organicell Regenerative Medicine, Inc., Organogenesis Holdings Inc., Reprise Biomedical, Inc., Sanofi S.A., Smith & Nephew PLC, Stryker Corporation, Tissue Regenix, Vascudyne, Inc., and Zimmer Biomet.

Market Segmentation & Coverage

This research report categorizes the Acellular Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Scaffold, market is studied across Cell Laden Hydrogel, Extracellular Matrix (ECM), and Fused Deposition Modeling (FDM).
• Based on Application, market is studied across Cardiology, Gastroenterology, Hepatology, Neurology, and Oncology.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of chronic diseases and age-related conditions
    • 5.1.1.2. Government initiatives to propel regenerative medicine and stem cell research
    • 5.1.1.3. Increased availability of acellular and smart biomaterials
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of skilled research personnel and limited reimbursement options
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements and R&D in acellular therapy worldwide
    • 5.1.3.2. Rising number of acellular therapy projects undertaken by hospitals and medical entities
  • 5.1.4. Challenges
    • 5.1.4.1. Complex regulations pertaining to regenerative medicine and acellular therapies
• 5.2. Market Segmentation Analysis
  • 5.2.1. Scaffold: Preference for extracellular matrix to support acellular therapy
  • 5.2.2. Application: Development of acellular therapy designed to target oncology tumor sites
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Acellular Therapy Market, by Scaffold

• 6.1. Introduction
• 6.2. Cell Laden Hydrogel
• 6.3. Extracellular Matrix (ECM)
• 6.4. Fused Deposition Modeling (FDM)

7. Acellular Therapy Market, by Application

• 7.1. Introduction
• 7.2. Cardiology
• 7.3. Gastroenterology
• 7.4. Hepatology
• 7.5. Neurology
• 7.6. Oncology

8. Americas Acellular Therapy Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Acellular Therapy Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Acellular Therapy Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
  • 11.3.1. Humacyte Announces Positive Top-Line Results from Phase 2/3 Trial of Human Acellular Vessel (HAV) in Treatment of Patients with Vascular Trauma
  • 11.3.2. FDA Approves Lantidra, a Cellular Therapy for Type 1 Diabetes
  • 11.3.3. Humacyte to Provide Human Acellular Vessels (HAVs) to Front-line Hospitals in Ukraine for Treatment of Vascular Trauma Injuries
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Allergan Inc. by Abbvie Inc.
• 2. AlloSource
• 3. Aziyo Biologics
• 4. Baxter International
• 5. Becton, Dickinson and Company
• 6. BioHorizons, Inc.
• 7. EnColl Corporation
• 8. Engitix Ltd
• 9. Fidia Farmaceutici S.p.A
• 10. GSK PLC
• 11. Humacyte, Inc.
• 12. In2Bones Global by CONMED Corporation
• 13. Integra LifeSciences Corporation
• 14. LifeNet Health
• 15. MiMedx Group
• 16. Organicell Regenerative Medicine, Inc.
• 17. Organogenesis Holdings Inc.
• 18. Reprise Biomedical, Inc.
• 19. Sanofi S.A.
• 20. Smith & Nephew PLC
• 21. Stryker Corporation
• 22. Tissue Regenix
• 23. Vascudyne, Inc.
• 24. Zimmer Biomet